Literature DB >> 19775825

Outcome with neck dissection after chemoradiation for N3 head-and-neck squamous cell carcinoma.

Levon Igidbashian1, Bernard Fortin, Louis Guertin, Denis Soulières, Geneviève Coulombe, Manon Belair, Danielle Charpentier, Jean-Claude Tabet, Phuc Felix Nguyen-Tan.   

Abstract

PURPOSE: To evaluate the role of neck dissection (ND) after chemoradiation therapy (CRT) for head and neck squamous cell carcinoma (HNSCC) with N3 disease. METHODS AND MATERIALS: From March 1998 to September 2006, 70 patients with HNSCC and N3 neck disease were treated with concomitant CRT as primary therapy. Response to treatment was assessed using clinical examination and computed tomography 6 to 8 weeks posttreatment. Neck dissection was not routinely performed and considered for those with less than complete response. Of the patients, 26 (37.1%) achieved clinical complete response (cCR) after CRT. A total of 31 (44.3%) underwent ND after partial response (cPR-ND). Thirteen patients (29.5%) did not achieve cCR and did not undergo ND for the following reasons: incomplete response/progression at primary site, refusal/contraindication to surgery, metastatic progression, or death. These patients were excluded from the analysis. Outcomes were computed using Kaplan-Meier curves and were compared with log rank tests.
RESULTS: Comparing the cCR and cPR-ND groups at 2 years, the disease-free survival was respectively 62.7% and 84.9% (p = 0.048); overall survival was 63.0% and 79.4% (p = 0.26), regional relapse-free survival was 87.8% and 96.0% (p = 0.21); and distant disease-free survival was 67.1% and 92.6% (p = 0.059). In the cPR-ND group, 71.0% had no pathologic evidence of disease (PPV of 29.0%).
CONCLUSIONS: Patients with N3 disease achieving regional cPR and primary cCR who underwent ND seemed to have better outcomes than patients achieving global cCR without ND. Clinical assessment with computed tomography is not adequate for evaluating response to treatment. Because of the inherent limitations of our study, further confirmatory studies are warranted. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 19775825     DOI: 10.1016/j.ijrobp.2009.05.034

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  7 in total

1.  Up-front neck dissection followed by concurrent chemoradiation in patients with regionally advanced head and neck cancer.

Authors:  Peter A Paximadis; Michael E Christensen; Greg Dyson; Dev P Kamdar; Ammar Sukari; Ho-Sheng Lin; George H Yoo; Harold E Kim
Journal:  Head Neck       Date:  2012-02-06       Impact factor: 3.147

2.  Clinical outcomes for patients presenting with N3 head and neck squamous cell carcinoma: Analysis of the National Cancer Database.

Authors:  Huaising C Ko; Shuai Chen; Aaron M Wieland; Menggang Yu; Andrew M Baschnagel; Gregory K Hartig; Paul M Harari; Matthew E Witek
Journal:  Head Neck       Date:  2017-07-24       Impact factor: 3.147

3.  Retrospective review of positron emission tomography with contrast-enhanced computed tomography in the posttreatment setting in human papillomavirus-associated oropharyngeal carcinoma.

Authors:  Jason Y K Chan; Giuseppe Sanguineti; Jeremy D Richmon; Shanthi Marur; Christine G Gourin; Wayne Koch; Christine H Chung; Harry Quon; Justin A Bishop; Nafi Aygun; Nishant Agrawal
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2012-11

4.  Outcomes for patients with head and neck squamous cell carcinoma presenting with N3 nodal disease.

Authors:  Matthew E Witek; Aaron M Wieland; Shuai Chen; Tabassum A Kennedy; Craig R Hullett; Evan Liang; Gregory K Hartig; Randy J Kimple; Paul M Harari
Journal:  Cancers Head Neck       Date:  2017-11-14

5.  Factors that affect PERCIST-defined test-retest comparability: an exploration of feasibility in routine clinical practice.

Authors:  Hui Yuan; Daniel King Hung Tong; Varut Vardhanabhuti; Pek-Lan Khong
Journal:  Clin Nucl Med       Date:  2015-12       Impact factor: 7.794

6.  Outcome of bimodality definitive chemoradiation does not differ from that of trimodality upfront neck dissection followed by adjuvant treatment for >6 cm lymph node (N3) head and neck cancer.

Authors:  Wan-Yu Chen; Tseng-Cheng Chen; Shih-Fan Lai; Tony Hsiang-Kuang Liang; Bing-Shen Huang; Chun-Wei Wang
Journal:  PLoS One       Date:  2019-12-03       Impact factor: 3.240

7.  N3 (> 6 cm) squamous cell carcinoma of the head and neck: outcomes and predictive factors in 104 patients.

Authors:  Selima Sellami; Jean Christophe Leclere; François Lucia; Yves Gobel; Arnaud Uguen; Jean Rousset; Dominique Gouders; Olivier Pradier; Rémi Marianowski; Ronan Abgral; Ulrike Schick
Journal:  Acta Otorhinolaryngol Ital       Date:  2021-06       Impact factor: 2.124

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.